<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3892B18D-3348-482D-A854-68726A9D52EE"><gtr:id>3892B18D-3348-482D-A854-68726A9D52EE</gtr:id><gtr:name>Seaside Therapeutics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:department>Biomedical Sciences</gtr:department><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3892B18D-3348-482D-A854-68726A9D52EE"><gtr:id>3892B18D-3348-482D-A854-68726A9D52EE</gtr:id><gtr:name>Seaside Therapeutics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4D643118-D00D-43C5-A6C4-6035292F169C"><gtr:id>4D643118-D00D-43C5-A6C4-6035292F169C</gtr:id><gtr:name>Novartis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/00FE3D00-46A6-4EDB-9672-1565C1E10DB8"><gtr:id>00FE3D00-46A6-4EDB-9672-1565C1E10DB8</gtr:id><gtr:name>Massachusetts Institute of Technology</gtr:name><gtr:address><gtr:line1>77 Massachusetts Avenue</gtr:line1><gtr:postCode>02139</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A0E38A76-22A8-4A96-B359-A22677D36A40"><gtr:id>A0E38A76-22A8-4A96-B359-A22677D36A40</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Conell</gtr:otherNames><gtr:surname>Kind</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0601584"><gtr:id>BCBF9CA9-5194-4F54-BD00-3497EF02CE6F</gtr:id><gtr:title>The roles of FMRP in cortical development</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601584</gtr:grantReference><gtr:abstractText>Fragile X syndrome is the most common form of mental retardation that can be inherited from ones? parents. It is caused by the absence of a single protein called the fragile X mental retardation protein or FMRP. Many of the severe cognitive symptoms of fragile X are associated with abnormal organization of the cerebral cortex, the region of the brain that is primarily responsible for mediating conscious sensory experiences, thoughts and actions.
Since the symptoms of fragile X syndrome first appear during childhood development it is likely that establishing how FMRP influences development of the brain will lead to a better understanding of fragile X syndrome and may suggest new or improved treatments. However, while most scientific investigations of FMRP have focused on its role in adults, very little attention has been given to the role of FMRP in the development of the cerebral cortex. We propose to address this issue by establishing where in the cerebral cortex FMRP is found during different stages of development and by determining how removal of FMRP, as occurs in FXS, influences the development and organization of the cerebral cortex.
The most promising framework established so far for designing treatments for fragile X syndrome is based on a recent theory which suggests that FMRP restricts neuronal communication by altering the function of a neurotransmitter receptor, called mGluR. The second part of our study will focus on how FMRP and mGluRs interact during development. We will carry out experiments that will establish if FMRP and mGluR5 interact during development and will determine if these interactions support the mGluR theory of fragile X syndrome.
Since the genetic factors that underlie the organizational development of the cerebral cortex are only beginning to be established, elucidation of the roles of FMRP in these processes will represent a significant contribution to understanding the mechanisms involved in development of the cerebral cortex. Moreover, our experiments will provide fundamental insights into the cellular mechanisms through which the altered brain function in fragile X patients arise and therefore may be important for discovery of new therapeutic treatments for mental retardation.</gtr:abstractText><gtr:technicalSummary>Fragile X syndrome (FXS) is the most common genetically inherited form of mental retardation. It results from the loss of a single protein, the fragile X mental retardation protein, FMRP. The mechanisms through which the absence of FMRP leads to the symptoms of FXS are not understood. Many of the cognitive and behavioural impairments found in fragile X individuals are associated with abnormal organization of the cerebral cortex. Although FXS is a disorder that emerges during childhood development, most experimental studies have focused on the functions of FMRP in the mature nervous system and little is known about the developmental roles of FMRP. Currently the most promising framework for designing treatments for FXS-associated symptoms is based on a hypothesis that suggests that FMRP acts to restrict signaling through group 1 metabotropic glutamate receptors (mGluRs). However, whether FMRP and group I mGluRs interact to control the development and organization of the cerebral cortex is not known.
We propose to test the hypothesis that failure of FMRP signaling during development leads to abnormal cortical organization and that a key developmental function of FMRP is to constrain processes driven by group 1 mGluR signaling. We will focus on the development of the primary somatosensory cortex, as this region is an excellent model system for the study of cortical development. To determine the developmental profile of FMRP expression in primary somatosensory cortex and the time points when altered cortical organization due to impaired FMRP signaling become apparent, we will apply state of the art techniques to analyse somatosensory cortex organisation during development in wild-type mice and in mice lacking Fmr1, the gene encoding FMRP. To establish if FMRP and mGluR5 signaling pathways interact during development and to determine whether these interactions support the mGluR theory of FXS, we will perform analysis of cortical organisation in mice lacking both Fmr1 and mGluR5, the predominant group 1 mGluR in the developing somatosensory cortex.
Since the genetic factors that underlie experience-dependent organization and refinement of cortical structures are only beginning to be established, elucidation of the role of FMRP in these processes will represent a significant contribution to understanding the mechanisms involved in cortical development. Moreover, the results of our experiments are likely to provide fundamental insights into the cellular mechanisms through which cognitive symptoms of FXS arise and may be important for discovery of new therapies for mental retardation.</gtr:technicalSummary><gtr:fund><gtr:end>2010-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>436547</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Novartis</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:department>Clinical Trials</gtr:department><gtr:description>Collaboration with Novartis Pharmaceuticals</gtr:description><gtr:id>BCC899B0-D287-4476-8184-C75F95FFA97B</gtr:id><gtr:impact>The finals outputs on the efficacy of the intervention will not be known until late 2012.</gtr:impact><gtr:piContribution>My role as Co-director of the Patrick Wild Centre and our MRC funded research on FXS was critical to Novartis choosing Edinburgh as their only UK based site for their pahse2b clinical trials</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Seaside Therapeutics</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pharmaceutical Strategies for FXS</gtr:description><gtr:id>13EDAC39-D973-479E-99AC-80F09DFE4D60</gtr:id><gtr:impact>The data was published in a high profile paper in Science Translational Medicine.</gtr:impact><gtr:partnerContribution>They also provided data and intellectual input to the project</gtr:partnerContribution><gtr:piContribution>Part of a research team examining the ability of arbaclofen (STX-209) to reverse the cellular alterations in a mouse model of FXS.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Massachusetts Institute of Technology (MIT)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Picower Centre MIT</gtr:department><gtr:description>Understanding the role of FMRP and TSC2 in Cortical Development</gtr:description><gtr:id>6FFAA902-BEE2-49EC-B707-119AF73CB1B1</gtr:id><gtr:impact>As noted above, we hope to have two joint manuscripts , on eon TSC and one on FMRP submitted in the coming months.</gtr:impact><gtr:partnerContribution>Lynsey Meikle spent a year at a laboratory at MIT learning in vivo record of visually-evoked potentials. She is now in the process of setting up this technology in Edinburgh. We also are collaborating with this lab and we expect that the data generated will be included in a manuscript on the role of FMRP in early synaptogenesis to be submitted for publication in the next few months.</gtr:partnerContribution><gtr:piContribution>The TSC project is part of an Lynsey Meikle's Sir Henry Wellcome fellowship. In term of the FXS project, the majority of the research as conducted in our laboratory under this grant. Our collaborators lab is testing whether the smaller than predicted increase in protein synthesis in Fmr1 ko mice results from an increase in protein degradation which will contribute one figure to a nine figure paper which we plan to submit soon.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>UMR 5297 (Institute for Interdisciplinary Neuroscience)</gtr:department><gtr:description>Examining the alteration in synaptic structure in FXS</gtr:description><gtr:id>A22545FB-3EC1-40CA-8AC2-0EF93887A8FE</gtr:id><gtr:impact>We have, for the first time, seen alterations in the morphological feature of dendritic spine neck width in FXS.</gtr:impact><gtr:partnerContribution>They are the experts in this form of microscopy.</gtr:partnerContribution><gtr:piContribution>My Postdoctoral Fellow visited Bordeaux to apply super-resolution microscopy to understand the cellular deficits associated with FXS.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Annual Sandoz Lecture</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>C31D4B83-3B55-42DC-BA37-76E0159B743B</gtr:id><gtr:impact>I presented a poster at a public day.

The aim is to give the public a glimpse into the Psychiatric and Neurological research that takes place at the University of Edinburgh.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Facility tour for the board members of Fragile X Society (UK)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:id>B7A6C3FB-FA46-497F-9742-E91E9AAA2845</gtr:id><gtr:impact>This has been an ongoing process of interaction between our newly formed Patrick Wild Centre for Research into Autism, Fragile X Syndrome and Intellectual Disabilities.

We are planning on conducting Phase 2b clinical trials with Novartis in the new year. These tours of our laboratories have been instrumental in building a relationship with the Fragile X Society, most of whom are parent of people with FXS.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Attended a conference on &quot;Ethics in Autism&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:id>AB383FC2-13A3-4AEA-AA89-05255F0FACEF</gtr:id><gtr:impact>Working scientist in the field of autism. Participated in informal discussion concerning therapeutic strategies and the ethical implications in treating autism.

Ongoing process and difficult to assess, but I continue to be invited to these events.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory Visits from Parents/Charities</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>06D3272C-AA59-45BD-B789-F225FAA15EBD</gtr:id><gtr:impact>We routinely give tours to interested parties of our laboratories and discuss our research on FXS and related disorders.

It is part of our strategies to engage the families affected by FXS and its related disorders as a key stake holder in our research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011,2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kili4-X thank you event</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:id>429DFB3A-AAE0-407F-A52C-CCB5083F3F8D</gtr:id><gtr:impact>It was an evening to say thank you to a group of donors to Fragile X research at the University of Edinburgh. They sponsored a climb of Mount Kilimanjaro.

We are in the process of setting up a Centre for Childhood Cognitive Impairment that focuses on FXS and Autism. These activities are designed to raise its profile.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patrick Wild Centre Open Day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>28D3DC2A-C5D2-4E56-8A5F-96707E3D2BBD</gtr:id><gtr:impact>The event was attended by approximately 100 family members of people affected with FXS, Autism and Autism Spectrum Disorders. This is an annual event that keep parents up-to-date on the current research being undertaken at the PWC as well as the status of ongoing clinical trials for FXS.

Continues to create a strong interaction between the families of affected individuals, the caregivers and the research scientists.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media inteviews</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>584EC284-EBDC-4482-AB45-75BF757FC272</gtr:id><gtr:impact>I have conducted interviews on radio (Five Live) and TV (STV), as well as for numerous newspapers including the Guardian, the Independent and the Times. Some of the interviews resulted from the Neuron paper (Harlow et al., 2010), but most were as a result of the opening of the Patrick Wild Centre, of which I am a Co-director, in November, 2010.

This is difficult to determine, but I hope it as increased the awareness of FXS and other forms of developmental neurological conditions as well as educating the public.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Medical Detectives Lecture (Open lecture to public)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>4B24371B-E7F4-4042-A594-741900EB9CB4</gtr:id><gtr:impact>Over 200 people from the public attended this lecture on Fragile X Syndrome, its developmental aetiology and potential therapeutic strategies in clinical trials

Brought additional from care social workers in contact with the Patrick Wild Centre.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kili4X conference open keynote talks from eminent Neuroscientists</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:id>8587B69F-7859-47B3-B34A-46DFCB074D43</gtr:id><gtr:impact>We held an international conference on Fragile X and related learning disabilities in August 2010. At the conference dinner and on the last day of the conference, parents of individuals with FXS and members of the Fragile X SOciety were invited to take part. Several pre-eminent researchers in the field from the University of Edinburgh, Rockefeller University and M.I.T, USA gave open lectures.

The feedback from the parents and the FX Society was very positive, which has strengthened the relationship of the FXS community and the Patrick Wild Centre.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome/NIH studentship to Aleks Domanski</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>12CA7A28-707B-4666-AF0D-D1FB84918129</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Autistica Fellowship</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Autistica</gtr:fundingOrg><gtr:id>5DCD6F3C-3E76-4C42-A9FC-90B2CC268313</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Simons Initiative for the Developing Brain</gtr:description><gtr:end>2022-03-02</gtr:end><gtr:fundingOrg>Simons Foundation Autism Research Initiative</gtr:fundingOrg><gtr:id>32A4A76D-0FFA-4FF9-B168-A27CB723527D</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1352057</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2020-08-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/P006213/1</gtr:fundingRef><gtr:id>0B19872D-CCBF-4C2E-BBF9-AD408DF6A077</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>60000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>FRAXA Research Grant</gtr:description><gtr:end>2009-04-02</gtr:end><gtr:fundingOrg>FRAXA Research Foundation</gtr:fundingOrg><gtr:id>45C225BA-2145-4A49-9AF0-CDAB02110552</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>64797</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Autistica</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Autistica</gtr:fundingOrg><gtr:id>56F04100-670C-4EFE-81A9-43C5DE28C39F</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Sir Henry Wellcome Postdoctoral Fellowship to Lynsey Meikle</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>CC6FA4D7-E5AE-40CA-8F5E-A72C41CCB658</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>828859</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/K014137/1</gtr:fundingRef><gtr:id>F2312C7C-94B3-47DC-9DC6-F96428A4C122</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Shirley Foundation Research Award</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Shirley Foundation</gtr:fundingOrg><gtr:id>1110C363-6613-4512-AFC8-1DD5199C3767</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5741F360-7646-4A67-B689-EF0B30072AA8"><gtr:id>5741F360-7646-4A67-B689-EF0B30072AA8</gtr:id><gtr:title>Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen.</gtr:title><gtr:parentPublicationTitle>Science translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e10d6af90c85406a9344d36113134714"><gtr:id>e10d6af90c85406a9344d36113134714</gtr:id><gtr:otherNames>Henderson C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1946-6234</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/03D50037-B445-4A2B-BE9E-72D6B4B6A669"><gtr:id>03D50037-B445-4A2B-BE9E-72D6B4B6A669</gtr:id><gtr:title>Experience-dependent regulation of functional maps and synaptic protein expression in the cat visual cortex.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc86dac82f8e096b84d410b666142f1e"><gtr:id>dc86dac82f8e096b84d410b666142f1e</gtr:id><gtr:otherNames>Jaffer S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6E949A9F-5DF1-4BFC-887A-F0117DB28B7C"><gtr:id>6E949A9F-5DF1-4BFC-887A-F0117DB28B7C</gtr:id><gtr:title>mGluR5 regulates glutamate-dependent development of the mouse somatosensory cortex.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/021708c7bd8709f4e4495505def72293"><gtr:id>021708c7bd8709f4e4495505def72293</gtr:id><gtr:otherNames>Wijetunge LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DE84E1EB-E3A5-4F76-9810-90B67E53B1E7"><gtr:id>DE84E1EB-E3A5-4F76-9810-90B67E53B1E7</gtr:id><gtr:title>Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99dd26415861350d64b11d0369403a16"><gtr:id>99dd26415861350d64b11d0369403a16</gtr:id><gtr:otherNames>Till SM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ACDCEC81-D7E7-4309-B770-02D7AFF85416"><gtr:id>ACDCEC81-D7E7-4309-B770-02D7AFF85416</gtr:id><gtr:title>Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c43ca11dee6dacdb11bbe7dcac3609a9"><gtr:id>c43ca11dee6dacdb11bbe7dcac3609a9</gtr:id><gtr:otherNames>Harlow EG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C0A93159-3388-4CAB-97FE-67D1EFB58111"><gtr:id>C0A93159-3388-4CAB-97FE-67D1EFB58111</gtr:id><gtr:title>Lifting the mood on treating fragile X.</gtr:title><gtr:parentPublicationTitle>Biological psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4e33c871f6b738a2cc11c8b34499eb5c"><gtr:id>4e33c871f6b738a2cc11c8b34499eb5c</gtr:id><gtr:otherNames>Osterweil EK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-3223</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0662E1B4-200C-4F61-8309-C9672D7F0808"><gtr:id>0662E1B4-200C-4F61-8309-C9672D7F0808</gtr:id><gtr:title>SynGAP isoforms exert opposing effects on synaptic strength.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0932978ff62bd64864d5ef234f198845"><gtr:id>0932978ff62bd64864d5ef234f198845</gtr:id><gtr:otherNames>McMahon AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C6510F8F-20F8-4B19-A8F2-309A611E354D"><gtr:id>C6510F8F-20F8-4B19-A8F2-309A611E354D</gtr:id><gtr:title>The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/21276c6c0852898613c4b12699518537"><gtr:id>21276c6c0852898613c4b12699518537</gtr:id><gtr:otherNames>Martel MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B433CD68-C109-4104-8985-4A2AD1F8AE7E"><gtr:id>B433CD68-C109-4104-8985-4A2AD1F8AE7E</gtr:id><gtr:title>Phospholipase C-beta1 signaling affects reproductive behavior, ovulation, and implantation.</gtr:title><gtr:parentPublicationTitle>Endocrinology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1069c5c4fc1b4d2f049a55c3dd4c080e"><gtr:id>1069c5c4fc1b4d2f049a55c3dd4c080e</gtr:id><gtr:otherNames>Filis P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0013-7227</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CF9CA6CA-0DFD-4258-836E-1CEAAF4A5FCF"><gtr:id>CF9CA6CA-0DFD-4258-836E-1CEAAF4A5FCF</gtr:id><gtr:title>Fgf receptor 3 activation promotes selective growth and expansion of occipitotemporal cortex.</gtr:title><gtr:parentPublicationTitle>Neural development</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b159c8623c4f566330211ae3226a5fe0"><gtr:id>b159c8623c4f566330211ae3226a5fe0</gtr:id><gtr:otherNames>Thomson RE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1749-8104</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AC726242-519F-4790-8E25-C3A8487DF521"><gtr:id>AC726242-519F-4790-8E25-C3A8487DF521</gtr:id><gtr:title>Pituitary adenylate cyclase-activating peptide induces long-lasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1.</gtr:title><gtr:parentPublicationTitle>Journal of neurochemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/7db6d84352d13ccbea74f0c757e4faec"><gtr:id>7db6d84352d13ccbea74f0c757e4faec</gtr:id><gtr:otherNames>Baxter PS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-3042</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/327E339B-3987-40F8-9138-A56A124C5B43"><gtr:id>327E339B-3987-40F8-9138-A56A124C5B43</gtr:id><gtr:title>The development and activity-dependent expression of aggrecan in the cat visual cortex.</gtr:title><gtr:parentPublicationTitle>Cerebral cortex (New York, N.Y. : 1991)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/162614660ebec7fa4e629dc69cc585ba"><gtr:id>162614660ebec7fa4e629dc69cc585ba</gtr:id><gtr:otherNames>Kind PC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1047-3211</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601584</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>